Characterization of CD137 ligand mediated human monocyte differentiation and their effects on t cell activities

CHARACTERIZATION OF CD137 LIGAND MEDIATED HUMAN MONOCYTE DIFFERENTIATION AND THEIR EFFECTS ON T CELL ACTIVITIES SHAQIREEN D/O KWAJAH M. M. (B.Sc (Hons), NUS) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHYSIOLOGY YONG LOO LIN SCHOOL OF MEDICINE NATIONAL UNIVERSITY OF SINGAPORE 2010 ACKNOWLEDGEMENTS I am deeply thankful to my supervisor, Associate Professor Herbert Schwarz, for his constant help, guidance and invaluable advices which has enabled me to develop an understanding for the project. I truly appreciate the encouragement and support that he has given me throughout the course of my study. Special thanks also go to my colleagues who have helped me in one way or another; to Jeanette and Ariel, for their guidance and mentorship when I first joined the lab; to Sun Feng, Doddy, Liang Kai and Weng Tong for their help in the radioactive work; to Shao Zhe, Julia, Dongsheng, Nurulhuda and Zulkarnain for the invaluable and fruitful discussions. I would also like to express my gratitude to all past and present members of the lab for their support and friendship and for the laughter that we shared during my time in the lab. Lastly, I would like to thank my family for their constant and unwavering support. i    TABLE OF CONTENTS ACKNOWLEDGEMENTS i TABLE OF CONTENTS ii ABSTRACT vii LIST OF TABLES ix LIST OF FIGURES x LIST OF ABBREVIATIONS xii 1. INTRODUCTION 1.1 The CD137 biology 1.1.1 The CD137 protein 1.1.2 Expression of CD137 and its role in immunity 1.1.3 CD137 and T cell responses 1.1.4 Immunotherapeutic potential of CD137 1.1.4.1 CD137 and tumour immunotherapy 1.1.4.2 CD137 and autoimmune diseases 1.2 The CD137 ligand biology 11 1.2.1 The CD137 ligand 11 1.2.2 Reverse signalling in the TNF superfamily 12 1.2.3 Expression of CD137L 14 1.2.4 Biological activities of CD137L signalling 14 1.2.4.1 CD137L stimulation and its role in myelopoiesis 14 1.2.4.2 Effects of monocytes in 16 1.2.4.3 Effects of CD137L stimulation in B cells and DCs 18 CD137L stimulation ii    1.2.5 1.2.4.4 Effects of CD137L stimulation in T cells 20 CD137L signal transduction 21 1.3 Immune responses in CD137 / CD137L deficient mice 22 1.4 Myeloid cells, its differentiation and function 24 1.4.1 Macrophage classifications and funtions 25 1.4.2 Monocyte derived DCs 27 1.4.3 DC immunotherapy and its challenges 29 1.4.4 Interactions between T cells and myeloid cells 32 1.4.4.1 T cell co-stimulation 32 1.4.4.2 Suppressive action on T cells 34 35 1.5 Research objectives 2. MATERIALS & METHODS 2.1 Recombinant protein, antibodies and reagents 38 2.2 Protein immobilization on tissue culture plates 39 2.3 Cells and cell culture 40 2.3.1 Cell lines 40 2.3.2 Isolation of PBMCs, monocytes and T cells 40 2.3.3 In vitro generation macrophages 2.4 2.5 of classical DCs and 42 Monocyte – T cell co-culture systems 43 2.4.1 Syngeneic monocyte – T cell co-cultures 43 2.4.2 Allogeneic MLR 43 Quantification of cell proliferation 44 2.5.1 Thymidine incorporation 44 2.5.2 CFSE dilution 45 iii    2.6 Determining suboptimal OKT3 concentration 45 2.7 Flow cytometric analysis 46 2.7.1 CFSE staining 46 2.7.2 Surface marker expression 47 2.7.3 Intracellular cytokine staining 47 2.7.4 Identification of transcription factors 48 2.7.5 Death receptor and ligand expression 48 2.7.6 Apoptosis assay 49 2.8 Identification of cell type undergoing apoptosis 49 2.9 Functional assays 50 2.9.1 Phagocytosis 50 2.9.2 Endocytosis 50 2.9.3 Oxidative burst 51 2.10 Potential cytolytic activity of T cells 51 2.10.1 Perforin expression 51 2.10.2 Flow cytometry based killing assay 52 2.11 Determination of the importance of soluble factors 53 2.11.1 Transwell assays 53 2.11.2 Transfer of soluble factors 53 2.12 Neutralization assays 54 2.12.1 Neutralization of death inducing factors 54 2.12.2 Neutralization of H2O2 by catalase 54 2.12.3 Cytokine neutralization 55 2.13 ELISA 55 2.14 Morphological changes 55 iv    2.15 Statistics 56 3. RESULTS 3.1 CD137L mediated inhibition of PBMC subsets 57 3.1.1 CD137L activation inhibits PBMC proliferation 57 3.1.2 CD137L activation selectively induce T cell apoptosis 59 3.1.3 CD137 mediated T cell apoptosis is dependent on monocytes 61 3.1.4 CD137 induced, monocyte dependent T cell apoptosis requires cell to cell contact 66 3.1.5 CD137 induced T cell apoptosis is independent of CD95 and TRAIL 68 3.1.6 CD137 mediated T cell apoptosis is dependent on ROS 75 3.2 3.3 Characterization of CD137L activated monocytes 77 3.2.1 CD137L signalling activates monocytes 77 3.2.2 CD137L signalling inhibits macrophage activities 78 3.2.3 CD137L activation promotes monocyte to DC differentiation 86 3.2.4 CD137L DCs and classical DCs are functionally different 94 Characterization of CD137L DC – T cell interactions 96 3.3.1 CD137L DC – T cell interactions are biphasic in nature 96 3.3.2 CD137L DCs promote a pro-inflammatory T cell phenotype 101 3.3.3 CD137L DC induce production of IFN- and IL-13 but not IL-17 in naïve T cells 110 3.3.4 CD137L DCs increase the killing activity of CD8 T cells 111 v    118 3.4 Summary 4. DISCUSSION 4.1 CD137L activated monocytes and their inhibitory activities on T cells 121 4.1.1 CD137 induces global inhibition of proliferation but selectively mediates T cell apoptosis 121 4.1.2 CD137 induced T cell apoptosis requires monocyte help 124 4.1.3 CD137 mediates T cell apoptosis independently of the extrinsic pathway of apoptosis 126 4.1.4 ROS in T cells is important in mediating CD137 induced MDCD 129 4.1.5 Physiological MDCD induced 131 CD137L activation induces monocyte differentiation that is stimulatory to T cells 134 4.2.1 CD137L signalling inhibits macrophage differentiation to 134 4.2.2 CD137 promote monocyte to differentiate to inflammatory DCs 138 4.2.3 CD137L DCs are phenotypically and functionally different from classical DCs 141 4.2.4 CD137L DCs promote inflammatory T cells with a high killing activity 144 4.2.5 The potential of using CD137L DCs as a tool in human immunotherapy 147 4.2 significance of CD137 monocyte 4.3 Conclusion 149 4.4 Future work 151 REFERENCES 154 APPENDICES 171 vi    ABSTRACT CD137 is a member of the tumour necrosis factor receptor (TNFR) superfamily that is expressed on a variety of immune cells. Its activation provides co-stimulatory signals to T cells and preferentially induces proliferation and activation of CD8 T cells. Similar to CD137, its ligand (CD137L), is also a membrane bound protein. Interaction between CD137 and CD137L not only induces signalling into the receptor bearing cell, it also initiates signalling into the ligand bearing cell. Hence, CD137 and its ligand participate in bidirectional signalling and stimulation of CD137L which results in signalling into ligand bearing cells has been termed as CD137 reverse signalling. In human monocytes, CD137L signalling delivers a potent activating signal. However, characterization of monocyte activation by CD137L has been restricted to the production of pro-inflammatory cytokines, adherence and morphological changes. This study shows that treatment of monocytes with recombinant CD137 protein, which stimulates CD137L on monocytes, also induces their differentiation to dendritic cells (DCs). This is evidenced by the increased endocytic capacity, up-regulation of co-stimulatory molecules and the ability to induce proliferation of naïve T cells. CD137 not only induces monocyte to DC differentiation but also promotes DC maturation. These DCs in turn inhibit development of regulatory T cells but induce T cell expression of perforin, IFN-, IL-13 and IL-17 and T cells with a high killing activity. Hence, recombinant CD137 protein as a sole factor can induce differentiation of monocytes to mature, inflammatory DCs that have a potent T cell vii    stimulatory capacity. As such, CD137 show potential in generating DCs that can be used in human immunotherapy. In contrast to these T cell stimulatory activities, CD137L stimulated monocytes also induce T cell apoptosis. CD137 mediated, monocyte dependent T cell apoptosis requires direct cell to cell contact and occurs independently of the extrinsic pathway of apoptosis. Instead, ROS are implicated in mediating T cell apoptosis. Hence, this study shows two contrasting activities of CD137L stimulated monocytes that are temporally separated; early induction of T cell apoptosis that is followed by its T cell stimulatory function. The pattern of CD137 induced, monocyte dependent T cell apoptosis show close similarities to infection induced T cell attrition which occurs during a number of viral infections. This early T cell apoptosis is suggested to be beneficial to the subsequent development of pathogen specific immune responses by (1) creating space in the lymphoid organ for expansion of antigen specific T cells and (2) depleting low affinity cross reactive T cells that can impede the development of proper immune responses. Hence, the two phases of CD137L mediated monocyte activation seem to be geared towards the development of an inflammatory immune response. viii    LIST OF TABLES 1. List of antibodies 38 2. Volume of protein in tissue culture wells 40 ix    References Kienzle G. and von Kempis J. (2000). CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol. 12, 73-82. Kim DK., Lee SC. and Lee HW. (2009). CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. Eur J Immunol. 39, 26172628. Kim J., Choi WS., La S., Suh JH., Kim BS., Cho HR., Kwon BS. and Kwon B. (2004). Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood. 105, 2206-13. Kim R., Emi M. and Tanabe K. (2006). Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol. 57, 545-553. Kim YJ., Kim SH., Mantel P. and Kwon BS. (1998). Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol. 28, 881890. Kim YJ., Li G. and Broxmeyer HE. (2002). 4-1BB ligand stimulation enhances myeloid dendritic cell maturation from human umbilical cord blood CD34+ progenitor cells. J Hematother Stem Cell Res. 11, 895-903. Kischkel FC., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer PH. and Peter ME. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579–5588. Kitagawa M., Suzuki H., Adachi Y., Nakamura H., Yoshino S. and Sumida T. (2001). Interferon-gamma enhances interleukin 12 production in rheumatoid synovial cells via CD40-CD154 dependent and independent pathways. J Rheumatol. 28, 1764-1771. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kämpgen E., Romani N. and Schuler G. (1996). High level IL-12 production by murine dendritic cells: up-regulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 184, 741-746. Kodelja V., Muller C., Tenorio S., Schebesch C., Orfanos CE. and Goerdt S. (1997). Differences in angiogenic potential of classically vs. alternatively activated macrophages, Immunobiology 197, 478–493. Krammer PH. (2000). CD95's deadly mission in the immune system. Nature. 407, 789-795. Kurts C. (2008). Th17 cells: a third subset of CD4+ T effector cells involved in organ-specific autoimmunity. Nephrol Dial Transplant. 23, 816-819. 160    References Kwon BS., and Weissman SM. (1989). cDNA sequences of two inducible Tcell genes. Proct. Natl. Acad Sci USA. 86, 1963-1967 Kwon BS., Hurtado JC., Lee ZH., Kwack KB., Seo SK., Choi BK., Koller BH., Wolisi G., Broxmeyer HE. and Vinay DS. (2002). Immune responses in 4-1BB (CD137)-deficient mice. J Immunol. 168, 5483-5490. Kwon BS., Kozak CA., Kim KK. and Pickard RT. (1994). Genomic organization and chromosomal localization of the T-cell antigen 4-1BB. J Immunol. 152, 2256-2262. Laderach D., Movassagh M., Johnson A., Mittler RS. and Galy A. (2002). 41BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol. 14, 1155-1167. Laderach D., Wesa A. and Galy A. (2003). 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol. 226, 37-44. Langstein J. and Schwarz H. (1999). Identification of CD137 as a potent monocyte survival factor. J. Leukoc. Biol. 65, 829-833 Langstein J., Becke FM., Sollner L., Krause G., Brockhoff G., Kreutz M., Andreesen R. and Schwarz H. (2000). Comparative analysis of CD137 and LPS effects on monocyte activation, survival and proliferation. Biochem. Biophys. Res. Commun. 273, 117-122. Langstein J., Michel J. and Schwarz H. (1999). CD137 induces proliferation and endomitosis in monocytes. Blood. 94, 3161-3168. Langstein J., Michel J., Fritsche J., Kreutz M., Andreesen R. and Schwarz H. (1998). CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J.Immunol. 160, 2488-2494. Lechmann M., Berchtold S., Hauber J. and Steinkasserer A. (2002) CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23, 273-275. Lee DA. and Molinaro GA. (2003). Activated peripheral T lymphocytes undergo apoptosis when cultured with monocytes activated by HLA class II ligation. Cell Immunol. 225, 101-112. Lee HW., Park SJ., Choi BK., Kim HH., Nam KO. and Kwon BS. (2002). 41BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol. 169, 4882-4888. Lee J., Lee EN., Kim EY., Park HJ., Chang CY., Jung DY., Choi SY., Lee SK., Lee KW., Kwon GY., Joh JW. and Kim SJ. (2005). Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett. 101, 210-216. 161    References Lee SC., Ju SA., Pack HN., Heo SK., Suh JH., Park SM., Choi BK., Kwon BS. and Kim BS. (2005). 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun. 73, 5144-5151. Lee SW., Park Y., So T., Kwon BS., Cheroutre H., Mittler RS. and Croft M. (2008). Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol. 9, 917926. Lee SW., Vella AT., Kwon BS. and Croft M.J. (2005). Enhanced CD4 T cell responsiveness in the absence of 4-1BB. Immunol. 174, 6803-6808. Lee YK., Mukasa R., Hatton RD. and Weaver CT. (2009). Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 21, 274-280. Lexberg MH., Taubner A., Forster A., Albrecht I., Richter A., Kamradt T., Radbruch A. and Chang HD. (2008). Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol. 38, 2654–2664. Li B., Lin J., Vanroey M., Jure-Kunkel M., and Jooss K. (2007). Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol. 125, 76-87. Li G., Kim YJ. and Broxmeyer HE. (2005). Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10(high) IL-12 absent dendritic cells with tolerogenic potential. J Immunol.174, 4706-4717. Li Q., Carr A., Ito F., Teitz-Tennenbaum S., Chang AE. (2003). Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 63, 2546-2552. Lindstedt M., Johansson-Lindbom B. and Borrebaeck CA. (2003). Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand J Immunol. 57, 305-310. Lippert U., Zachmann K., Ferrari DM., Schwarz H., Brunner E., Mahbub-Ul Latif AH, Neumann C. and Soruri A. (2008). CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol. 38, 1024-1032. Lisignoli G., Toneguzzi S., Cattini L., Pozzi C. and Facchini A. (1998). Different expression pattern of cytokine receptors by human osteosarcoma cell lines. Int J Oncol. 12, 899-903. Liu YJ. (2005). IPC: professional type interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 23, 275-306. Losana G., Rigamonti L., Borghi I., Assenzio B., Ariotti S., Jouanguy E., Altare F., Forni G., Casanova JL. and Novelli F. (2002). Requirement for both 162    References IL-12 and IFN-gamma signaling pathways in optimal IFN-gamma production by human T cells. Eur J Immunol. 32, 693-700. Lynch DH. (2008). The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 222, 277-86. MacDonald KP., Rowe V., Bofinger HM., Thomas R., Sasmono T., Hume DA. and Hill GR. (2005). The colony-stimulating factor receptor is expressed on dendritic cells during differentiation and regulates their expansion. J Immunol. 175, 1399-1405. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A. and Locati M. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686. Mantovani A., Sozzani S., Locati M., Allavena P. and Sica A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549–555. Martinez FO., Sica A., Mantovani A. and Locati M. (2008). Macrophage activation and polarization. Front Biosci. 13, 453-461. Maus MV., Thomas AK., Leonard DG., Allman D., Addya K., Schlienger K., Riley JL. and June CH. (2002). Ex vivo expansion of polyclonal and antigenspecific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 20, 143-148. McNally JM., Zarozinski CC., Lin MY., Brehm MA., Chen HD. and Welsh RM. (2001). Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J Virol. 75, 5965-5976. Melero I., Johnston JV., Shufford WW., Mittler RS. and Chen L. (1998). NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 190, 167-172. Melero I., Shuford WW., Newby SA., Aruffo A., Ledbetter JA., Hellström KE., Mittler RS. and Chen L. (1997). Monoclonal antibodies against the 41BB T-cell activation molecule eradicate established tumors. Nat Med. 3, 682-685. Michel J., Langstein J., Hofstadter F. and Schwarz H. (1998). A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis, Eur. J. Immunol. 28, 290–295 Michel J., Pauly S., Langstein J., Krammer PH. and Schwarz H. (1999). CD137-induced apoptosis is independent of CD95. Immunology. 98, 42-46. 163    References Middendorp S., Xiao Y., Song JY., Peperzak V., Krijger PH., Jacobs H. and Borst J. (2009). CD137 ligand are predisposed to develop germinal centerderived B-cell lymphoma. Blood. 114, 2280-2289. Miller RE., Jones J., Le T., Whitmore J., Boiani N., Gliniak B. and Lynch DH. (2002). 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 169, 1792-1800. Mittler RS., Bailey TS., Klussman K., Trailsmith MD. and Hoffmann MK. (1999). Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med. 190, 1535-1540. Mittler RS., Foell J., McCausland M., Strahotin S., Niu L., Bapat A. and Hewes LB. (2004). Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res. 29, 197-208. Morelli AE. and Thomson AW. (2007). Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 7, 610-621. Morse MA., Nair SK., Mosca PJ., Hobeika AC., Clay TM., Deng Y., Boczkowski D., Proia A., Neidzwiecki D., Clavien PA., Hurwitz HI., Schlom J., Gilboa E. and Lyerly HK. (2003). Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21, 341-349. Mosser DM. and Edwards JP. (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 8, 958-969. Munder M., Eichmann K. and Modolell M. (1998). Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J. Immunol. 160, 5347–5354. Munn DH., Shafizadeh E., Attwood JT., Bondarev I., Pashine A. and Mellor AL. (1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 189, 1363-1372. Mytar B., Siedlar M., Woloszyn M., Ruggiero I., Pryjma J. and Zembala M. (1999). Induction of reactive oxygen intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. Br. J. Cancer 79, 737–743. Nabeshima S, Murata M, Kikuchi K, Ikematsu H, Kashiwagi S, Hayashi J. (2002). A reduction in the number of peripheral CD28+CD8+T cells in the acute phase of influenza. Clin Exp Immunol. 128, 339-346. Nakamoto Y., Kaneko S. and Kobayashi K. (2001). Monocyte-dependent cell death of T lymphocyte subsets in chronic hepatitis C. Immunol Lett. 78, 169174. 164    References Noël W., Raes G., Ghassabeh GH., De Baetselier P. and Beschin A. (2004). Alternatively activated macrophages during parasite infections, Trends Parasitol. 20, 126–133. Osada T., Clay TM., Woo CY., Morse MA. and Lyerly HK (2006). Dendritic cell-based immunotherapy. Int Rev Immunol. 25, 377-413. Oyaizu N., Adachi Y., Hashimoto F., McCloskey TW., Hosaka N., Kayagaki N., Yagita H., and Pahwa S. (1997). Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J.Immunol. 158, 2456-2463. Palma C., Binaschi M., Bigioni M., Maggi CA. and Goso C. (2004). CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer. 108, 390-398. Pauly S., Broll K., Wittmann M., Giegerich G. and Schwarz H. (2002). CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol. 72, 35-42. Peacock CD., Kim SK. and Welsh RM. (2003). Attrition of virus-specific memory CD8+ T cells during reconstitution of lymphopenic environments. J Immunol. 171, 655-663. Pervaiz S. and Clement MV. (2007). Superoxide anion: oncogenic reactive oxygen species? Int J Biochem Cell Biol. 39, 1297-1304. Pollok KE., Kim YJ., Hurtado J., Zhou Z., Kim KK. and Kwon BS. (1994). 41BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol. 24, 367-374. Pollok KE., Kim YJ., Zhou Z., Hurtado J., Kim KK., Pickard RT. and Kwon BS. (1993). Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 150, 771-781. Polte T., Jagemann A., Foell J., Mittler RS. and Hansen G. (2007). CD137 ligand prevents the development of T-helper type cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells. Clin Exp Allergy. 37, 1374-1385. Quek BZ., Lim YC., Lin JH., Tan TE., Chan J., Biswas A. and Schwarz H. (2010). CD137 enhances monocyte-ICAM-1 interactions in an E-selectindependent manner under flow conditions. Mol Immunol. 47, 1839-1847. Randolph GJ, Angeli V. and Swartz MA. (2005). Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5, 617-628. Reali C., Curto M., Sogos V., Scintu F., Pauly S., Schwarz H. and Gremo F. (2003). Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2. J Neurosci Res. 74, 67-73. 165    References Reichardt VL., Milazzo C., Brugger W., Einsele H., Kanz L., Brossart P. (2003). Idiotype vaccination of multiple myeloma patients using monocytederived dendritic cells. Haematologica. 88, 1139-1149. Rodríguez PC. and Ochoa AC. (2008). Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev. 222, 180–191. Rodriguez PC., Quiceno DG. and Ochoa AC. (2007). L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 109, 1568–1573. Saito K., Ohara N., Hotokezaka H., Fukumoto S., Yuasa K., Naito M., Fujiwara T. and Nakayama K. (2004). Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis. J Biol Chem. 279, 13555-13563. Saoulli K., Lee SY., Cannons JL., Yeh WC., Santana A., Goldstein MD., Bangia N., DeBenedette MA., Mak TW., Choi Y. and Watts TH. (1998). CD28-independent, TRAF2-dependent costimulation of resting T cells by 41BB ligand. J Exp Med. 187, 1849-1862. Schabowsky RH., Elpek KG., Madireddi S., Sharma RK., Yolcu ES., Bandura-Morgan L., Miller R., MacLeod KJ., Mittler RS. and Shirwan H. (2009). A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28, 512-522. Schneider-Schaulies S. and Schneider-Schaulies J. (2009). Measles virusinduced immunosuppression. Curr Top Microbiol Immunol. 330, 243-269. Schwarz H. (2005). Biological activities of reverse signal transduction through CD137 ligand. J. Leukoc .Biol. 77, 281-286. Schwarz H., Arden K. and Lotz M. (1997). CD137, a member of the tumor necrosis factor receptor family is located on chromosome 1p36, in a cluster of related genes, and colocalizes with several malignancies. Biochem. Biophys. Res. Commun. 235, 699-703. Schwarz H., Blanco FJ., von Kempis J., Valbracht J., and Lotz M. (1996). ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood. 87, 2839-2845. Schwarz H., Tuckwell J. and Lotz M. (1993). A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growthfactor/ tumor-necrosis-factor receptor family. Gene. 134, 295-298. Schwarz H., Valbracht J., Tuckwell J., von Kempis J. and Lotz M. (1995). ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood. 85, 1043-1052. 166    References Seo SK., Choi JH., Kim YH., Kang WJ., Park HY., Suh JH., Choi BK., Vinay DS. and Kwon BS. (2004). 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med. 10, 1088-1094. Setareh M., Schwarz H. and Lotz M. (1995). A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene. 164, 311-315. Shao Z. and Schwarz H. (2010). CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol. Epub ahead of print. Shortman K. and Liu YJ. (2002). Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2, 151-161. Shuford WW., Klussman K., Tritchler DD., Loo DT., Chalupny J., Siadak AW., Brown TJ., Emswiler J., Raecho H., Larsen CP., Pearson TC, Ledbetter JA., Aruffo A. and Mittler RS. (1997). 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 186, 47-55. Snijders A., Kalinski P., Hilkens CM. and Kapsenberg ML. (1998). Highlevel IL-12 production by human dendritic cells requires two signals. Int Immunol. 10, 1593-1598. Söllner L., Shaqireen D/O Kwajah MM., Wu JT. and Schwarz H. (2007). Signal transduction mechanisms of CD137 ligand in human monocytes. Cell Signal. 19, 1899-1908. Song E., Ouyang N., Horbelt M., Antus B., Wang M. and Exton MS. (2000), Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts, Cell. Immunol. 204, 19–28. Sprick, MR., Weigand MA., Rieser E., Rauch CT., Juo P., Blenis J., Krammer PH. and Walczak H. (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors and and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 12, 599–609. Stärck L., Scholz C., Dörken B. and Daniel PT. (2005). Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol. 35, 1257-1266. Sun Y., Chen HM., Subudhi SK., Chen J., Koka R., Chen L. and Fu YX. (2002). Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 8, 1405-1413. Sun Y., Chen JH. and Fu Y. (2004). Immunotherapy with agonistic antiCD137: two sides of a coin. Cell Mol Immunol. 1, 31-36. Sytwu HK., Lin WD., Roffler SR., Hung JT., Sung HS., Wang CH., Cheng TL., Tsou SC., Hsi SC. and Shen KL. (2003). Anti-4-1BB-based 167    References immunotherapy for autoimmune diabetes: lessons from a transgenic nonobese diabetic (NOD) model. J Autoimmun. 21, 247-254. Tammana S., Huang X., Wong M., Milone MC., Ma L., Levine BL., June CH., Wagner JE., Blazar BR. and Zhou X. (2010). 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against Bcell malignancies. Hum Gene Ther. 21, 75-86. Tan JT., Whitmire J K., Ahmed R., Pearson TC. and Larsen CP. (1999). 41BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163, 4859-4868. Trapani JA. and Smyth MJ. (2002). Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2, 735-747. Tripathi P. and Hildeman D. (2004). Sensitization of T cells to apoptosis--a role for ROS? Apoptosis. 9, 515-523. Tuyaerts S., Aerts JL., Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K. and Bonehill A. (2007). Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 56, 1513-1537. Van Ginderachter JA., Movahedi K., Ghassabeh GH., Meerschaut S., Beschin A., Raes G., De Baetselier P. (2006). . Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 211, 487-501. Veldhoen M., Hocking RJ., Atkins CJ., Locksley RM. and Stockinger B. (2006). TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179–189. Verhagen CE., de Boer T., Smits HH., Verreck FA., Wierenga EA., Kurimoto M., Lammas DA., Kumararatne DS., Sanal O., Kroon FP., van Dissel JT., Sinigaglia F. and Ottenhoff TH. (2000). Residual type immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J Exp Med. 192, 517-528. Verreck FA., de Boer T., Langenberg TM., Hoeve MA., Kramer M., Vaisberg E., Kastelein R., Kolk A., de Waal-Malefyt R. and Ottenhoff TH. (2004). Human IL-23-producing type macrophages promote but IL-10-producing type macrophages subvert immunity to (myco)bacteria, Proc. Natl. Acad. Sci. USA 101, 4560–4565. Vinay DS. and Kwon BS. (2006) Genes transcripts and proteins of CD137 receptor and ligand. In CD137 Pathway: Immunology and Diseases. L.Chen, ed. (NY: Springer) Vinay DS. and Kwon BS (2011). 4-1BB signaling beyond T cells. Cell Mol Immunol. Epub ahead of print. 168    References von Kempis J., Schwarz H. and Lotz M. (1997). Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin. Osteoarthritis Cartilage. 5, 394-406. Vremec D., Pooley J., Hochrein H., Wu L. and Shortman K. (2000). CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164, 2978–2986. Walczak H. and Krammer PH. (2000).The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 256, 58-66. Wen T., Bukczynski J. and Watts TH. (2002). 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 168, 4897-4906. Wesch D, Marx S., and Kabelitz D. (1998). Monocyte-dependent death of freshly isolated T lymphocytes: induction by phorbolester and mitogens and differential effects of catalase. J.Immunol. 161, 1248-1256. Wilcox RA., Flies DB., Zhu G., Johnson AJ., Tamada K., Chapoval AI., Strome SE., Pease LR. and Chen L. (2002). Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 109, 651-659. Wilcox RA., Tamada K., Strome SE. and Chen L. (2002). Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 169, 4230-4236. Wiley SR., Schooley K., Smolak PJ., Din WS., Huang CP., Nicholl JK., Sutherland GR., Smith TD., Rauch C., Smith CA., et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3, 673-682. Wu M., Ao XZ., Hegen M., Morimoto C. And Schlossman SF. (1996). Requirement of Fas(CD95), CD45, and CD11a/CD18 in monocyte-dependent apoptosis of human T cells. J.Immunol. 157, 707-713. Xu L., Kitani A., Fuss I. and Strober W. (2007). Cutting edge: regulatory T cells induce CD4+CD25−Foxp3− T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol. 178, 6725–6729. Young JW., Szabolcs P. and Moore MA. (1995). Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumour necrosis factor. J. Exp. Med. 182, 1111-1119. Zamzami N. and Kroemer G. (2001). The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol. 2, 67-71. 169    References Zheng G., Wang B. and Chen A. (2004). The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol. 173, 24282434. Zheng Y. and Rudensky AY. (2007). Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 8, 457–462. Zhong XS., Matsushita M., Plotkin J., Riviere I. and Sadelain M. (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18, 413-420. Zhou LJ. and Tedder TF. (1996). CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A. 93, 2588-2592. Zhou Z., Kim S., Hurtado J., Lee ZH., Kim KK., Pollok KE. and Kwon BS. (1995). Characterization of human homologue of 4-1BB and its ligand. Immunol Lett. 45, 67-73. Zhu G., Flies DB., Tamada K., Sun Y., Rodriguez M., Fu YX. and Chen L. (2001). Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice. J Immunol. 167, 2671-2676. 170    APPENDICES     Appendix APPENDIX TISSUE CULTURE MEDIA A1.1 RPMI 1640 For a L preparation, A1.2 RPMI powder (Sigma-Aldrich) 16.35 g L-glutamine (200mM) (Gibco, Invitrogen) 10 ml Sodium bicarbonate (Sigma-Aldrich) 2.0 g MilliQ water Top up to 1L R10 For a L preparation, A1.3 RPMI-1640 medium 900 ml FBS (Biowest) 100 ml R10 + P/S For a L preparation, A1.4 R10 990 ml Penicillin / Streptomycin (Gibco, Invitrogen) 10 ml IMDM IMDM powder (Sigma-Aldrich) 17.7 g L-glutamine (200mM) 10 ml Sodium bicarbonate 3.02 g MilliQ water Top up to 1L 171    Appendix A1.5 I10 IMDM medium 900 ml FBS 100 ml The pH of all culture media was adjusted to 7.4. Medium was sterile filtered through a 0.22µm filter membrane before use. 172    Appendix APPENDIX BUFFERS FOR ISOLATION OF PBMCS AND PBMC SUBSETS A2.1 PBS + 2mM EDTA For a L preparation, A2.2 10 X PBS (1st Base) 100 ml EDTA (0.5M) (1st Base) ml MilliQ water Top up to 1L RBC lysis buffer For a L preparation, A2.3 NH4Cl (Sigma-Aldrich) 8.29 g NaHCO3 (Sigma-Aldrich) 0.84 g EDTA (0.5M) 23 µl MilliQ water Top up to 1L MACS buffer For a L preparation, 10 X PBS 100 ml EDTA (0.5M) ml 0.5% BSA (Biowest) 5g The pH of buffers was adjusted to 7.4. Buffers were sterile filtered through a 0.22µm filter membrane before use. 173    Appendix APPENDIX MISCELLANEOUS BUFFERS A3.1 Trypsin-EDTA For a 50 ml preparation, A3.2 0.5% Trypsin-EDTA (Gibco, Invitrogen) ml 10 X PBS ml MilliQ water Top up to 50 ml 10 mM EDTA in PBS For a 50 ml preparation, A3.3 EDTA (0.5M) ml 10 X PBS ml MilliQ water Top up to 50 ml FACS buffer For a L preparation, FBS ml Sodium azide (Sigma-Aldrich) 0.2 g 10 X PBS 100 ml MilliQ water Top up to 1L The pH of buffers was adjusted to 7.4. Trypsin-EDTA and 10 mM EDTA in PBS were sterile filtered through a 0.22µm filter membrane before use. 174    [...]... activation on monocytes, a subtype of myeloid cells Hence, this introduction gives an overview of the protein of interest, CD137, and its interaction with its ligand The concept of reverse signalling will be addressed and current literature on the effects of CD137 reverse signalling is highlighted Further, a review on the current knowledge of monocytes, their differentiation, function and interactions... contact between monocytes and T cells 67 8 CD137 treatment increases expression of death receptors on T cells 70 9 CD137 treatment increases expression of CD95L and TRAIL on T cells 71 10 CD137 mediated T cell apoptosis is independent of the CD95 receptor / ligand and TRAIL / death receptor systems 74 11 Inhibition of ROS completely blocks CD137 induced T cell apoptosis 76 12 CD137L signalling activates... Introduction 1.2.4.2 Effects of CD137L stimulation in monocytes Studies have shown that the activation of CD137L on monocytes induces production of pro-inflammatory cytokines: IL-8, IL-6 and TNF (Langstein et al, 1998; Langstein et al, 2000; Sollner et al, 2007) and a down-regulation of IL-10, a cytokine associated with monocyte deactivation (Langstein et al, 1998) The cytokine profile of CD137L activated... proliferation and cytokine production (Pollok et al, 1993; Alderson et al, 1993; Hurtado et al, 1995) Further, CD137 has been shown to inhibit activation induced cell death (AICD) during restimulation of activated T cells by up-regulation of the antiapoptotic protein, Bcl-xL (Hurtado et al, 1997; Starck et al, 2005) Within the T cell population, most of the studies on CD137 co-stimulation have focused on the... regulatory function of NK cells and that CD137 is important in mediating cross talk between the innate and adaptive immune responses Apart from immune cells, CD137 expression has been reported on other cell types Drenkard et al have reported that CD137 is expressed on blood vessel walls at sites of inflammation where CD137 is thought to facilitate the extravasation of monocytes into the inflammatory tissues... without doubt, that CD137L stimulation activates monocytes However, more studies need to be done to more closely determine how monocyte functions and differentiation are affected by CD137 This may provide an insight as to how CD137L signalling in monocytes can influence the bigger immunological network 1.2.4.3 Effects of CD137L stimulation in B cells and DCs Unlike studies on CD137L activation in monocytes,... B cell activation (Pauly et al, 2002) CD137 stimulation has also been shown to induce proliferation of NK cells and their production of IFN- without increasing the cytolytic potential of these cells Rather, CD137 activated NK cells seem to be important in enhancing cytolytic potential of CD8 T cells (Melero et al, 1998; Wilcox et al, 2002) These studies show that CD137 stimulation affects the immune... all, these data suggest that CD137L stimulation activates peripheral monocytes Apart from being an activating factor, CD137L activation enhanced monocyte survival, proliferation and endomitosis Primary peripheral monocytes that were treated with CD137 showed an ability to survive even after twelve days of culture while untreated monocytes could only survive for up to 6 days post isolation (Langstein and. .. important in eradicating tumours once the tumour has been established Activated, tumour specific T cells would then express CD137 and systemically administered anti -CD137 antibodies can then activate the CD137 expressing T cells, enhancing the CTL 7    Introduction activity and therapeutic potential of the cells This was supported by studies which showed that administration of antibodies late in the tumour... mediate production of pro-inflammatory cytokines In this case, interaction of CD137L seems to be independent of its receptor but depends on TLR agonists (Kang et al, 2007) Independent interaction from the receptor further suggests the possibility of an alternative ligand However, the identity of this alternative ligand has yet to be determined 1.2.2 Reverse signalling in the TNF superfamily Most ligands . ligand Treg Regulatory T cell  INTRODUCTION Introduction 1  This thesis focuses on the activities of CD137 ligand (CD137L) activation on monocytes, a subtype of myeloid cells contrasting activities of CD137L stimulated monocytes that are temporally separated; early induction of T cell apoptosis that is followed by its T cell stimulatory function. The pattern of CD137 induced,. used in human immunotherapy. In contrast to these T cell stimulatory activities, CD137L stimulated monocytes also induce T cell apoptosis. CD137 mediated, monocyte dependent T cell apoptosis